Key result
In vivo treatment with anti-PD-1 or -PD-L1 blocking antibodies increased myocardial inflammation in mice with viral myocarditis, whereas anti-PD-1 stimulating antibodies decreased it.
Why the study?
Does treatment with anti-PD-1 or anti-PD-L1 monoclonal antibodies alter myocardial inflammation in a murine model of Coxsackievirus B3 acute myocarditis?
Does treatment with anti-PD-1 or anti-PD-L1 monoclonal antibodies alter myocardial inflammation in a murine model of Coxsackievirus B3 acute myocarditis?
The PD-1/PD-L1 pathway plays a pivotal role in suppressing myocardial inflammation in viral myocarditis, highlighting its potential as an immunotherapeutic target.
May exacerbate viral myocarditis inflammation with PD-1/PD-L1 blockade; leaves open immunotherapeutic targeting in patients.
OBJECTIVE: This study was designed to investigate the roles of programmed death-1 (PD-1) and PD-1 ligands (PD-L) in the development of murine acute myocarditis caused by Coxsackievirus B3. PD-1/PD-L belong to the CD28/B7 superfamily, and the PD-1/PD-L pathway is known to transduce a negative immunoregulatory signal that antagonizes the T-cell receptor-CD28 signal and inhibits T-cell activation. METHODS: We first analyzed the expression of PD-L1/PD-L2 on cardiac myocytes in vivo and in vitro. Second, we examined the effects of in vivo treatment with an anti-PD-1, PD-L1, or PD-L2 monoclonal antibodies on the development of myocardial inflammation in C3H/He mice infected with Coxsackievirus B3. Third, to investigate the effects of anti-PD-1 monoclonal antibody treatment on the activation of the infiltrating cells, we examined the expression of interleukin (IL)-2, interferon (IFN)-gamma, CD40 ligand (CD40L), Fas ligand (FasL), and perforin as activation markers in mouse hearts by a semiquantitative PCR method. RESULTS: PD-L1 was markedly induced on cardiac myocytes with acute myocarditis. In vivo anti-PD-1 or -PD-L1 blocking monoclonal antibody treatment increased the myocardial inflammation whereas anti-PD-1 stimulating monoclonal antibody treatment decreased the myocardial inflammation, and anti-PD-L2 monoclonal antibody treatment had no effect. Anti-PD-1 monoclonal antibody treatment significantly increased the expression of IFN-gamma, FasL, CD40L, perforin, and Coxsackievirus B3 genomes in myocardial tissue. CONCLUSION: Our findings strongly suggest that the PD-1/PD-L1 pathway played a pivotal role in suppressing myocardial inflammation and raise the possibility of immunotherapy by stimulating the PD-1/PD-L1 pathway to prevent myocardial damage in viral myocarditis.
No takes yet. Share an insight, caveat, or question.
SEKO et al. (2007) studied murine acute myocarditis caused by Coxsackievirus B3. anti-PD-1, PD-L1, or PD-L2 monoclonal antibodies was evaluated on myocardial inflammation. In vivo treatment with anti-PD-1 or -PD-L1 blocking antibodies increased myocardial inflammation in mice with viral myocarditis, whereas anti-PD-1 stimulating antibodies decreased it.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: